Literature DB >> 31347543

Guillain-Barre syndrome in North Indian children: Clinical and serial electrophysiological features.

Sandeep Yadav1, Puneet Jain2, Suvasini Sharma1, Virendra Kumar1, Satinder Aneja1.   

Abstract

BACKGROUND: Guillain-Barre syndrome (GBS) is a common acquired polyneuropathy in children. AIM: To describe the clinical and serial electrophysiological features along with short-term outcomes of children with GBS in north India. SETTING AND
DESIGN: This was a prospective study conducted at a tertiary care pediatric hospital in north India.
MATERIALS AND METHODS: Consecutive children, aged 2 to 18 years, with GBS, presenting within 4-weeks of onset of weakness, diagnosed on clinical and/or electrophysiological grounds, were enrolled. The enrolled children underwent a detailed clinical-assessment followed by nerve conduction studies. Repeat nerve conduction studies were performed after 2-weeks of the first study to determine changes in the electrophysiological subtype. The patients were followed up for 3 months.
RESULTS: Thirty-six children were studied. The mean age at presentation was 5.1 years [standard deviation (SD): 2.1]. The mean medical research council (MRC)-sum-score at admission was 24.1 (SD: 10.4). Thirty-three children (91%) had loss of ambulation, 24 (66%) had cranial nerve involvement, and 6 (16.6%) required ventilation. At presentation, 20 had acute motor axonal neuropathy (AMAN), 13 had acute inflammatory demyelinating polyneuropathy (AIDP), 2 had in-excitable nerves, and 1 had normal findings. Four children, initially diagnosed as AIDP, had AMAN with reversible conduction failure on the repeat study. The final classification was AMAN in 25 (69.4%; 95% confidence interval (CI), 51.9-83.7%) and AIDP in 9 children (25%; 95% CI, 12.1-42.2%). Only one patient was nonambulatory at a 3-month follow-up (n = 32). The Erasmus GBS outcome score was 2 in 2 (5.6%), 3 in 5 (13.9%), 4 in 26 (72.2%), and 5 in 3 (8.3%) patients.
CONCLUSIONS: The serial electrophysiological studies were helpful in establishing the final correct diagnosis.

Entities:  

Keywords:  Erasmus GBS outcome score; Guillain-Barre syndrome; reversible conduction failure; serial electrophysiological studies

Mesh:

Year:  2019        PMID: 31347543     DOI: 10.4103/0028-3886.263191

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  4 in total

1.  Diagnosing SARS-CoV-2 associated Guillain-Barre syndrome requires cerebro-spinal-fluid studies.

Authors:  Josef Finsterer; Fulvio A Scorza; Carla A Scorza; Ana C Fiorini
Journal:  J Neuroimmunol       Date:  2021-05-13       Impact factor: 3.478

2.  Impact of the COVID-19 Pandemic on the Frequency, Clinical Spectrum and Outcomes of Pediatric Guillain-Barré Syndrome in India: A Multicentric Ambispective Cohort Study.

Authors:  Divyani Garg; Rajinder K Dhamija; Aditya Choudhary; Ritu Shree; Sujit Kumar; Priyanka Samal; Abhishek Pathak; Pamidimukkala Vijaya; Yareeda Sireesha; Sruthi S Nair; Sanjay Sharma; Soaham Desai; Human P Sinha; Ayush Agarwal; Ashish Upadhyay; M V Padma Srivastava; Rohit Bhatia; Awadh K Pandit; Rajesh K Singh; Alisha Reyaz; P M Yogeesh; Manish Salunkhe; Vivek Lal; Manish Modi; Gagandeep Singh; Monika Singla; Samhita Panda; Maya Gopalakrishnan; Inder Puri; Sudhir Sharma; Bismay Kumar; Prashant K Kushwaha; Harshadkumar Chovatiya; Teresa Ferreira; Sanjeev K Bhoi; Manish Bhartiya; Subhash Kaul; Anuja Patil; Neeharika L Mathukumalli; Madhu Nagappa; P Praveen Sharma; Aneesh Basheer; Dileep Ramachandran; Neetha Balaram; Jospeh Sebastian; Venugopalan Y Vishnu
Journal:  Ann Indian Acad Neurol       Date:  2021-11-17       Impact factor: 1.383

3.  A Stitch in Time Defeats the Landry-Guillain-Barré Strohl Syndrome.

Authors:  Prateek Upadhyay; Richa Saroa
Journal:  Cureus       Date:  2022-09-11

4.  Clinical and Electrophysiological Factors Predicting Prolonged Recovery in Children with Guillain-Barré Syndrome.

Authors:  Ekta Agarwal; Ankita Bhagat; Kavita Srivastava; Bina Thakore; Sujit Jagtap; Umesh Kalane; Surekha Rajadhyaksha
Journal:  Indian J Pediatr       Date:  2021-06-07       Impact factor: 1.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.